It would be the first life sciences IPO since BioAge Labs' offering in September. Drug developer Maze Therapeutics Inc.'s rollercoaster ride is leading to the Bay Area's first biotech IPO filing of ...

Maze fits the mold of biotechs that have pulled off successful offerings recently: The seven-year old startup, which raised ...

Maze said it earned $9.03 million for the nine months ended Sept. 30, 2024, compared with a loss of $73.84 million in the ...

Maze Therapeutics has filed for an initial public offering with the Securities and Exchange Commission. The San Francisco-based human genetics biotech company didn't say Tuesday how many shares it ...

Based in South San Francisco, Maze has several programs in its pipeline. The furthest along is MZE829, a small molecule inhibitor targeting a protein called apolipoprotein L1, or APOL1.

Maze Therapeutics (MAZE), which is developing treatments for chronic kidney disease, has filed to raise $100M through an ...

As a laboratory that researches the physical and chemical properties of matter, some of Lawrence Livermore National ...

Following last month’s fatal shooting of an insurance executive, healthcare’s largest investor meeting has assumed a higher security posture.

The firm, which plans to use the ticker symbol "MAZE" on the Nasdaq, develops drugs designed to mimic the protective effects ...